Aurinia Pharmaceuticals (AUPH) Cash from Investing Activities (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Cash from Investing Activities data on file, last reported at -$18.1 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 158.26% year-over-year to -$18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.9 million (down 488.78% YoY) and the FY2025 annual result came in at -$32.8 million, down 183.46% from the prior year.
• Cash from Investing Activities grew to -$18.1 million in Q1 2026, from -$36.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $49.2 million in Q1 2024 to a low of -$53.0 million in Q1 2022.
• A 5-year average of -$4.6 million and a median of -$10.6 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 2631.8% — and 2024, when it slumped 588.69%.
• Tracing AUPH's Cash from Investing Activities over 5 years: stood at -$3.0 million in 2022, then plunged by 107.32% to -$6.3 million in 2023, then soared by 726.87% to $39.2 million in 2024, then plunged by 193.71% to -$36.8 million in 2025, then soared by 50.81% to -$18.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$18.1 million (Q1 2026), -$36.8 million (Q4 2025), and -$13.8 million (Q3 2025), per Business Quant data.